Stories
On Lilly's request to the FDA to revoke the Emergency Use Authorization of bamlanivimab alone in the U.S., and what it means for Canada
Learn More
“We’re not using all the tools we have available to us, and it doesn’t make sense.”
Learn More
The Availability of Bamlanivimab in Canada
Learn More
A Comment on PMPRB Regulations
Learn More
Equity and Canada’s Drug Coverage System
Learn More
The Difference between Cost-effectiveness and Affordability
Learn More
Taking a Closer Look at Access to New Medicines
Learn More
Global Biotech Week: Let’s Celebrate Innovative Partnerships
Learn More